Inhibition of DNA damage response pathway using combination of DDR pathway inhibitors and radiation in treatment of acute lymphoblastic leukemia cells
- PMID: 33960207
- DOI: 10.2217/fon-2020-1072
Inhibition of DNA damage response pathway using combination of DDR pathway inhibitors and radiation in treatment of acute lymphoblastic leukemia cells
Abstract
An alarming increase in acute lymphoblastic leukemia cases among children and adults has attracted the attention of researchers to discover new therapeutic strategies with a better prognosis. In cancer cells, the DNA damage response (DDR) pathway elements have been recognized to protect tumor cells from various stresses and cause tumor progression; targeting these DDR members is an attractive strategy for treatment of cancers. The inhibition of the DDR pathway in cancer cells for the treatment of cancers has recently been introduced. Hence, effective treatment strategies are needed for this purpose. Chemotherapy in combination with radiotherapy is considered a potential therapeutic strategy for acute leukemia. This review aims to assess the synergistic effects of these inhibitors with irradiation for the treatment of leukemia.
Keywords: DNA damage; DNA damage response; acute lymphoblastic leukemia; radiation; response pathway inhibitors.
Plain language summary
Lay abstract Acute lymphoblastic leukemia (ALL) is a blood malignancy that is caused by the high proliferation of lymphoid precursors in bone marrow and peripheral blood, and it is one of the common malignancies among children and adults. Novel therapeutic strategies are increasingly being studied to suppress cancer cells. DNA damage response pathways have developed in cancer cells that protect tumor cells from chemotherapy and radiotherapy and cause relapse and treatment failure. Effective drugs in ALL treatment can suppress cancer cells through several mechanisms, such as inducing DNA damage in cancer cells. However, due to the active repair systems in cancer cells, treatment may fail. Recently, the inhibition of these repair pathways and the combination of DNA damage response pathway inhibitors with chemotherapy and radiotherapy in cancer treatment have been studied. The purpose of this review is to outline the synergistic effects of DNA damage response pathway inhibitors and radiation in the death of leukemic cells.
Similar articles
-
Breaking the DNA damage response to improve cervical cancer treatment.Cancer Treat Rev. 2016 Jan;42:30-40. doi: 10.1016/j.ctrv.2015.11.008. Epub 2015 Nov 24. Cancer Treat Rev. 2016. PMID: 26643553 Review.
-
Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.Curr Med Chem. 2019;26(8):1425-1445. doi: 10.2174/0929867325666180117102233. Curr Med Chem. 2019. PMID: 29345572 Review.
-
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.J Hematol Oncol. 2020 Sep 21;13(1):126. doi: 10.1186/s13045-020-00959-2. J Hematol Oncol. 2020. PMID: 32958072 Free PMC article. Review.
-
Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.J Exp Clin Cancer Res. 2018 Jun 28;37(1):129. doi: 10.1186/s13046-018-0790-7. J Exp Clin Cancer Res. 2018. PMID: 29954437 Free PMC article.
-
DNA damage response in patients with pediatric Acute Lymphoid Leukemia during induction therapy.Leuk Res. 2017 Mar;54:59-65. doi: 10.1016/j.leukres.2017.01.013. Epub 2017 Jan 11. Leuk Res. 2017. PMID: 28109975
Cited by
-
The Journey of DDR1 and DDR2 Kinase Inhibitors as Rising Stars in the Fight Against Cancer.Int J Mol Sci. 2021 Jun 18;22(12):6535. doi: 10.3390/ijms22126535. Int J Mol Sci. 2021. PMID: 34207360 Free PMC article. Review.
-
Benzothiazole and Chromone Derivatives as Potential ATR Kinase Inhibitors and Anticancer Agents.Molecules. 2022 Jul 20;27(14):4637. doi: 10.3390/molecules27144637. Molecules. 2022. PMID: 35889508 Free PMC article.
-
Combinatorial targeting of telomerase and DNA-PK induces synergistic apoptotic effects against Pre-B acute lymphoblastic leukemia cells.Mol Biol Rep. 2024 Jan 22;51(1):163. doi: 10.1007/s11033-023-09087-9. Mol Biol Rep. 2024. PMID: 38252348
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources